High Note Wealth LLC Decreases Stock Holdings in Pfizer Inc. (NYSE:PFE)

High Note Wealth LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 27.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 8,545 shares of the biopharmaceutical company’s stock after selling 3,209 shares during the quarter. High Note Wealth LLC’s holdings in Pfizer were worth $246,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. Front Street Capital Management Inc. lifted its position in shares of Pfizer by 4.3% in the first quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock worth $268,000 after purchasing an additional 215 shares in the last quarter. Graves Light Lenhart Wealth Inc. lifted its position in shares of Pfizer by 1.4% in the second quarter. Graves Light Lenhart Wealth Inc. now owns 19,863 shares of the biopharmaceutical company’s stock worth $729,000 after purchasing an additional 281 shares in the last quarter. Infrastructure Capital Advisors LLC raised its position in Pfizer by 5.2% during the second quarter. Infrastructure Capital Advisors LLC now owns 5,751 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 284 shares in the last quarter. Castleview Partners LLC raised its position in Pfizer by 2.4% during the first quarter. Castleview Partners LLC now owns 12,207 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 287 shares in the last quarter. Finally, United Bank raised its position in Pfizer by 0.6% during the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after acquiring an additional 290 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on PFE shares. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research report on Thursday, January 4th. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. UBS Group cut their price objective on shares of Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a research report on Thursday, December 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Friday, March 1st. Finally, Barclays dropped their price target on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Thursday, December 14th. Twelve research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus target price of $36.88.

Pfizer Stock Up 0.7 %

PFE opened at $27.77 on Thursday. Pfizer Inc. has a fifty-two week low of $25.61 and a fifty-two week high of $42.22. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The firm’s fifty day moving average price is $27.47 and its two-hundred day moving average price is $29.47. The company has a market capitalization of $157.25 billion, a P/E ratio of 77.14, a P/E/G ratio of 1.24 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. During the same quarter in the previous year, the company earned $1.14 earnings per share. The business’s revenue was down 41.3% compared to the same quarter last year. On average, analysts anticipate that Pfizer Inc. will post 2.22 EPS for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.